What do you think of this senstence from the PR? D
Post# of 148166
“CytoDyn has now opened a clinical trial (NCT03838367) that is assessing the efficacy of leronlimab (PRO 140) in metastatic triple negative breast cancer and will measure CTCs in the enrolled patients.”